Drug updated on 4/17/2024
| Dosage Form | Injection (intravenous; 100 mg) |
| Drug Class | Hydrolytic lysosomal enzymes |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of patients 1 year of age and older with late-onset Pompe disease (lysosomal acid alpha-glucosidase [GAA] deficiency)
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Nexviazyme (avalglucosidase alfa-ngp) Prescribing Information. | 2021 | Genzyme Corporation Cambridge, MA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Assessment report: Nexviadyme. | 2022 | EMA |
| Clinical and pharmacoeconomic combined report: avalglucosidase alfa (Nexviazyme). | 2022 | CADTH |